*June 2022*
Presented by CEC ONCOLOGY with Dr. Helena Yu, Dr. Natasha B. Leighl, and EGFR Resisters Cofounder Jill Feldman
This Rapid Recap provides a responsive, timely, and incisive overview of data presented at the 2022 Clinical Oncology Annual Meeting (ASCO), and offers expert insights into the shifting management landscape for metastatic EGFR+ NSCLC. These data will be placed in context of the established paradigm, with key scientific messages and pivotal points highlighted for audience takeaway. The session concludes with a patient-led roundtable evaluating the multifarious burden of financial toxicity on optimal and equitable outcomes in NSCLC.
Watch the video recap here.
Download the presentation slides here.
